

PB 104 of 2024

National Health (Originator Brand) Amendment Determination 2024 (No. 3)

I, Nikolai Tsyganov, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 26 September 2024

NIKOLAI TSYGANOV

Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division Department of Health and Aged Care

Contents

1 Name	1
2 Commencement	1
3 Authority	1
4 Schedules	
Schedule 1—Amendments	2
National Health (Originator Brand) Determination 2015 (PB 100 of 2015)	2

1 Name

This instrument is the National Health (Originator Brand) Amendment Determination 2024 (No. 3).

This instrument may also be cited as PB 104 of 2024.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information					
Column 1	Column 2	Column 3			
Provisions	Commencement	Date/Details			
1. The whole of this instrument	1 October 2024				

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99ADB(6B) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Originator Brand) Determination 2015 (PB 100 of 2015)

1 Schedule 1, (after table item 204A)

Repeal:

204B	Rivastigmine	Exelon	Oral	
		Exelon Patch 5 Exelon Patch 10 Exelon Patch 15	Transdermal	
204C	Rizatriptan	Maxalt		

Substitute:

204B	Rivaroxaban	Xarelto	Oral	
204C	Rivastigmine	Exelon	Oral	
		Exelon Patch 5 Exelon Patch 10 Exelon Patch 15	Transdermal	
204D	Rizatriptan	Maxalt		

National Health (Originator Brand) Amendment Determination 2024 (No. 3)